BioSpace News Archive

Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke.

Vera Therapeutics, Inc., a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced the pricing of its public offering of 4,993,067 shares of its Class A common stock at a price to the public of $15.00 per share.

Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunomodulatory therapies for prevalent inflammatory conditions, announced the appointment of Elizabeth Varki Jobes, Esq. to the Company’s Board of Directors.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, the company’s President and Chief Executive Officer, is scheduled to present at the 11th Annual SVB Leerink Global Healthcare Conference.

Elios Therapeutics, a biopharmaceutical company developing innovative personalized therapeutic cancer vaccines, today announced the appointment of Mark H.N. Corrigan, M.D. as Chairman of the Board of Directors effective immediately.

Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $60 million Series A financing round.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), announced today that it will be hosting a booth at the upcoming Life Sciences Day on the Hill on February 16, 2022, at the Utah State Capital Building.

Micro-Tech Endoscopy has introduced the first self-expanding tracheobronchial nitinol y-stent.

Acera Surgical, Inc. (Acera), today announced its first patient enrollment in a multicenter, head-to-head clinical study evaluating Restrata® for the treatment of non-healing venous leg ulcers (VLUs).

The Eli Lilly and Company Foundation, Inc., a tax-exempt organization supported by Eli Lilly and Company, has elected Cynthia Cardona as its president.